(R)-N-(1-azabicyclo[2.2.2]oct-3-yl)-7-hydroxythieno[3,2-b]-pyridine-6-carboxamide | 1055328-70-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: (R)-N-(1-azabicyclo[2.2.2]oct-3-yl)-7-hydroxythieno[3,2-b]-pyridine-6-carboxamide
• 英文别名: Pumosetrag；N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-7-oxo-4H-thieno[3,2-b]pyridine-6-carboxamide
• CAS: 1055328-70-5；153062-94-3
• 化学式: C₁₅H₁₇N₃O₂S
• 分子量: 303.385
• InChiKey: AFUWQWYPPZFWCO-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  89.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists
  申请人：Saito Daisuke Roland

  公开号：US20090062333A1

  公开（公告）日：2009-03-05

  The invention provides 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds of formula (I): wherein R 2 , R 7 , and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

  本发明提供了式(I)的8-氮杂双环[3.2.1]辛基-2-羟基苯甲酰胺化合物： 式中，R2、R7和m如说明书中所定义，或其药用可接受的盐，这些化合物是μ阿片受体的拮抗剂。本发明还提供了包含这些化合物的药物组合物，使用这些化合物治疗与μ阿片受体活性相关病症的方法，以及用于制备这些化合物的过程和中间体。
• Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
  申请人：Long Daniel D.

  公开号：US20090062334A1

  公开（公告）日：2009-03-05

  The invention provides heteroarylene substituted 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R 1 , R 2 , A, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

  该发明提供了异芳基取代的8-氮杂双环[3.2.1]辛烷化合物，化学式为(I)：其中R1、R2、A和m在规范中有定义，或其药用可接受的盐，这些化合物是μ阿片受体拮抗剂。该发明还提供了包含这种化合物的药物组合物，使用这种化合物治疗与μ阿片受体活性相关的疾病的方法，以及用于制备这种化合物的过程和中间体。
• AMINO- AND AMIDO-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
  申请人：Trapp Sean G.

  公开号：US20090247627A1

  公开（公告）日：2009-10-01

  The invention provides amino- and amido-aminotetralin compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

  这项发明提供了式(I)的氨基和酰胺氨基四氢萘化合物：其中R1、R2、R3、R4、R5、R6、R7和n在说明书中有定义，或其药用盐，它们是μ阿片受体拮抗剂。该发明还提供了包含这些化合物的药物组合物，使用这些化合物治疗与μ阿片受体活性相关的疾病的方法，以及用于制备这些化合物的过程和中间体。
• Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
  申请人：Long Daniel D.

  公开号：US20090062335A1

  公开（公告）日：2009-03-05

  The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R 1 , R 2 , R 3 , and a are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

  该发明提供了新颖的8-azabicyclo[3.2.1]辛烷化合物，化学式为(I)：其中R1、R2、R3和a在规范中有定义，或其药用可接受盐，这些化合物是μ阿片受体拮抗剂。该发明还提供了包括这些化合物的药物组合物，使用这些化合物治疗与μ阿片受体活性相关的疾病的方法，以及用于制备这些化合物的工艺和中间体。
• AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
  申请人：Leadbetter Michael R.

  公开号：US20090149465A1

  公开（公告）日：2009-06-11

  The invention provides aminotetralin compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

  该发明提供了公式（I）的氨基四氯化合物：其中R1、R2、R3、R4、R5、R6、R7、n和m在规范中定义，或其药用可接受盐，这些化合物是μ阿片受体的拮抗剂。该发明还提供了包含这种化合物的药物组合物，使用这种化合物治疗与μ阿片受体活性相关的疾病的方法，以及用于制备这种化合物的过程和中间体。